- Active, not recruiting
NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With RRMM (LUMMICAR STUDY 1)
Updated: May 26, 2022
(LUMMICAR STUDY 1)
NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.
Sponsor
Collaborators
Beijing Chao Yang Hospital
The First Affiliated Hospital of Soochow University
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Tianjin Medical University General Hospital
First Affiliated Hospital of Zhejiang University
Beijing Hospital
Shanghai Tongji Hospital, Tongji University School of Medicine
First Affiliated Hospital of Wenzhou Medical University
Xiangya Hospital of Central South University
Peking University People's Hospital
Qilu Hospital of Shandong University
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier: NCT03975907
Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
First Posted : June 5, 2019
Click here for details on Clinicaltrials.gov
Anti-BCMA-targeting CAR-T Cells (Code C176023)
Genetic: CAR-BCMA T cells
autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T cells CT053
BCMA Car-T (CT053)
CAR-BCMA T cells CT053
Drug: Fludarabine
Drug: Cyclophosphamide
Poster #2821: Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Poster #1751: Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors
704.Cellular Immunotherapies: Clinical| November 5, 2021
Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors
704.Cellular Immunotherapies: Clinical| November 5, 2021
Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Location
China
China, Beijing: Beijing Chaoyang hospital
China, Jiangsu: The First Affiliated Hospital Of Soochow University